Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intensive Care Unit and Hospital Mortality for non-COVID Critically ill Patients Before, and During the COVID-19 Pandemic in Alberta Hospitals: Retrospective, Observational Cohort Study.

Journal of intensive care medicine·2026

Same author

Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial.

Thorax·2025

Same author

Adjudication of Codes for Identifying Sepsis in Hospital Administrative Data by Expert Consensus.

Critical care medicine·2024

Same author

Adjunctive Midodrine Therapy for Vasopressor-Dependent Shock in the ICU: A Systematic Review and Meta-Analysis.

Critical care medicine·2024

Same author

Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis.

PharmacoEconomics - open·2024

Same author

Treatment of persistent focalized Q fever: time has come for an international randomized controlled trial.

The Journal of antimicrobial chemotherapy·2024

Search research articles

Related Experiment Video

Updated: May 10, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Severe community-acquired pneumonia.

Wendy I Sligl¹, Thomas J Marrie

¹Division of Infectious Diseases and Critical Care Medicine, University of Alberta, 3C1.12 WMC 8440 112 Street, Edmonton, Alberta T6G 2B7, Canada. wsligl@ualberta.ca

Critical Care Clinics

|July 9, 2013

Summary

Severe community-acquired pneumonia (CAP) requires intensive care and has high costs. This review covers CAP

Area of Science:

Pulmonology
Critical Care Medicine
Infectious Diseases

Background:

Severe community-acquired pneumonia (CAP) is a significant cause of intensive care unit (ICU) admission.
CAP is associated with substantial morbidity, mortality, and healthcare expenditure.

Purpose of the Study:

To provide a comprehensive review of severe CAP.
To summarize current knowledge on epidemiology, diagnosis, treatment, and prognosis.

Main Methods:

Review of current practice guidelines.
Analysis of scoring systems (PSI, CURB-65, IDSA/ATS) for severity and prognosis prediction.
Discussion of complications and prevention strategies.

Main Results:

Keywords:

Community-acquired pneumonia Intensive care Lung Pulmonary sepsis Respiratory failure

More Related Videos

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

Related Experiment Videos

Last Updated: May 10, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

Severe CAP necessitates ICU admission, presenting significant clinical challenges.

Established scoring systems aid in predicting CAP severity, prognosis, and optimal site of care.

Understanding complications and prevention is crucial for patient outcomes.

Conclusions:

This review synthesizes key aspects of managing severe CAP.
Evidence-based guidelines and scoring systems are vital for clinical decision-making.
Effective management strategies encompass diagnosis, treatment, complication avoidance, and prevention.